New World ACCESS Consortium White Paper Finds U.S. Most-Favored-Nation Pricing Is Reshaping How Biopharma Plans Global Launches

A survey of 16 biopharmaceutical manufacturers finds MFN pricing uncertainty is changing launch planning and pricing governance more than prompting broad portfolio withdrawals. 81% identified the EU5 as a potential non-launch risk for at least one pipeline asset, 69% cited delayed-launch risk, and 69% reported more centralized global pricing governance; 75% reported a higher evidence bar, while 38% increased HEOR or real-world evidence investment. The authors characterize the findings as directional and warn that more selective launch sequencing could disproportionately affect smaller markets and rare-disease patients.

Analysis

MFN’s investable signal is a change in launch economics, not yet evidence of a broad reduction in U.S. drug prices. If international prices enter the reference basket, delaying or foregoing lower-price markets could protect U.S. pricing at the cost of overseas volume and patient access; the near-term U.S. revenue effect is therefore ambiguous. The risk is uneven: assets dependent on smaller markets, rare-disease launches, or broad geographic reach may face tougher sequencing decisions, while differentiated products with strong evidence and pricing flexibility could be relatively resilient. The survey’s small, confidential sample is directional, and reported changes in evidence requirements exceed reported incremental evidence investment—a potential execution constraint rather than proof of higher spending or better outcomes.

Over the next 1–3 months, policy design matters more than the survey: watch the reference-country basket, timing rules, exemptions, and company commentary on launch plans. Over 6–18 months, selective launches could reduce international uptake and invite payer or political responses, while making trial evidence and global pricing governance more valuable. A broad pharma short is not supported: policy details, actual launch changes, and company-level exposure are missing. The thesis weakens if final rules exclude foreign launch prices or provide workable protections for low-price markets; it strengthens if companies disclose delayed launches or revise geographic access plans.

Key Decisions for Investors

• No immediate sector trade: treat this as a policy-monitoring signal, not evidence of realized earnings pressure.
• Build an exposure watchlist from company disclosures: flag pipeline assets relying on EU5 or smaller-market launches, rare-disease portfolios, and planned launch timing; do not infer exposure from this survey alone.
• At the next policy or earnings catalyst, favor relative positioning only if company-level evidence confirms a gap: underweight firms delaying lower-price markets versus firms with differentiated products and demonstrated evidence-generation capacity.
• Track final MFN rules and company updates for reference-country scope, exemptions, and launch sequencing; a documented delay or geographic launch withdrawal would strengthen the downside case, while broad exemptions would weaken it.